Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PEG-ELECTROLYTES

All products: general benefit

JampLyte · DIN 02378329 · · Pd-4L Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
JampLyte · DIN 02378329 Manufacturer: Jamp Pharma Corporation; listing date 2026-06-30 Health Canada: Marketed since 2025-06-17 · brand JAMPLYTE · ATC A06AD65 MACROGOL, COMBINATIONS · form Powder · route Oral · ingredients POTASSIUM CHLORIDE 3.04 G/280G, SODIUM BICARBONATE 6.76 G/280G, SODIUM CHLORIDE 5.84 G/280G, POLYETHYLENE GLYCOL 3350 238.2 G/280G, SODIUM SULFATE 22.96 G/280G · company Jamp pharma corporation · schedule Ethical
Check this DIN again · Health Canada product record

JampLyte: Formulary list price $16.4640/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.4640 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86414 · Verify on the e-Formulary ↗ (DIN 02378329)

Source record
DIN 02378329: JampLyte Raw flags: sec3=Y Item: 401200040; group id 549; item number 1481; lccId None; manufacturer id JPC Source form: Pd-4L Pk; strength: None Recorded listing: General benefit Source prices (unrounded): $16.4640; ministry $16.4640 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02378329 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86414
Interchangeable products
Colyte · DIN 00677442 · not recorded PegLyte Powder · DIN 00777838 · $16.4640
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378329
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (40:12 Replacement Agents) and how they are covered

Matched class: 40:12 Replacement Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ELECTROLYTE & DEXTROSE 40:12 Replacement Agents

ELECTROLYTE & DEXTROSE

· 2 products · General benefit · strengths: · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:12
Full class listing Related classes: 40:18 Potassium-Removing Resins, 40:28 Diuretics, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: constipation
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: BISACODYL BISACODYL · General benefit INDICATIONS AND CLINICAL USE DULCOLAX is indicated for: • Relief of occasional constipation • Under medical supervision, for the preparation of diagnostic procedures, in pre- and postoperative treatment, and in conditions which require defecation to be facilitated. PM: https://pdf.hres.ca/dpd_pm/00076868.PDF; date November 3, 2022; DIN 00003875; fetched 2026-09-10 Product monograph PRUCALOPRIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS RESOTRAN® (prucalopride succinate tablets) is indicated for: • The treatment of chronic idiopathic constipation in adult female patients in whom laxatives failed to provide adequate relief. PM: https://pdf.hres.ca/dpd_pm/00073288.PDF; date NOV 08, 2023; DIN 02377012; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults Colyte® (PEG 3350 and Electrolytes) is indicated for:  bowel cleansing prior to colonoscopy or barium enema x-ray examination or surgical procedures requiring a clean colon.  the treatment of constipation https://pdf.hres.ca/dpd_pm/00061814.PDF PM date: March 25, 2021 Source product: COLYTE; DIN 00677442; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.